PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28483563-9	2017	We also confirmed that losartan could reduce the apoptotic ratio of cells in the lung by modulating the phosphorylation of JNK and leak of cytochrome C to cytosol.	Losartan	23-31	mitogen-activated protein kinase 8	Rattus norvegicus	123-126	
18158102-5	2008	Ang II-induced JNK phosphorylation was abolished by co-treatment with the AT(1) receptor antagonist, losartan, but not by PD123319 (an AT(2) receptor antagonist).	Losartan	101-109	mitogen-activated protein kinase 8	Rattus norvegicus	15-18	
16298339-6	2006	Angiotensin II rapidly induced phosphorylation of p38 MAPK and JNK, both of which were inhibited by DPI, NAC, antisense gp91phox, and the selective AT1 receptor antagonist, losartan.	Losartan	173-181	mitogen-activated protein kinase 8	Rattus norvegicus	63-66	
11040228-4	2000	Losartan, an AT(1) receptor antagonist, prevented the onset of cardiac hypertrophy and regressed the progression of cardiac hypertrophy in SHRSP, being accompanied by the reduction of JNK activity and activator protein-1 (AP-1) activity in SHRSP.	Losartan	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	184-187	
14740078-9	2003	Losartan did not change p-p38, increased p-JNK-1, and did not change pERK-1/-2, PKCepsilon, or cGMP.	Losartan	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	43-46	
14521934-3	2003	Treatment of neurons cultured from neonatal rat hypothalamus and brainstem with Ang II (100 nM) showed a time-dependent increase in AP-1 DNA binding and this effect was inhibited by the AT(1) receptor antagonist, losartan (1 microM), the PI3-K inhibitor, LY294002 (10 microM), and the JNK inhibitor, JNK inhibitor II (100 nM).	Losartan	213-221	mitogen-activated protein kinase 8	Rattus norvegicus	285-288	
14521934-3	2003	Treatment of neurons cultured from neonatal rat hypothalamus and brainstem with Ang II (100 nM) showed a time-dependent increase in AP-1 DNA binding and this effect was inhibited by the AT(1) receptor antagonist, losartan (1 microM), the PI3-K inhibitor, LY294002 (10 microM), and the JNK inhibitor, JNK inhibitor II (100 nM).	Losartan	213-221	mitogen-activated protein kinase 8	Rattus norvegicus	300-303	
9421421-4	1998	Ang II caused time-dependent increases in the activation of FRK and JNK, effects completely inhibited by the AT1 receptor antagonist losartan but not by the Ang II type 2 (AT2) receptor blocker PD123,319.	Losartan	133-141	mitogen-activated protein kinase 8	Rattus norvegicus	68-71	
28707739-7	2017	Losartan, an angiotensin II type 1 receptor (AT1-R) blocker, abolished the APC-stimulated increase of LVDP and reduced PKCepsilon, Akt, Erk1/2, JNK, and p38.	Losartan	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	144-147	
24466104-11	2014	ERK and JNK expression were regulated in the presence of Losartan, while angiotensin, Tyr-betaRI, total and Tyr-phosphorylated PI3K expression were elevated in the OBL group.	Losartan	57-65	mitogen-activated protein kinase 8	Rattus norvegicus	8-11	
22648547-6	2012	The convergence of two independent signal pathways, the RhoA GTPase and pERK and concurrent inhibition of JNK MAP kinase, were required for the apoptotic response in 14 day kidney obstructed tubular cells either with or without Losartan treatment.	Losartan	228-236	mitogen-activated protein kinase 8	Rattus norvegicus	106-109	
23277113-7	2013	Losartan also blocked the Ang II-induced phosphorylation of ERK1/2, p38 MAPK, and SAPK/JNK.	Losartan	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	87-90	
22399333-7	2012	The selective AT(1) receptor antagonist, Losartan, prevented Ang III-induced JNK phosphorylation.	Losartan	41-49	mitogen-activated protein kinase 8	Rattus norvegicus	77-80	
21627650-8	2012	The phosphorylated JNK protein was induced by hypoxia and was abolished by pretreatment with SP600125, losartan (an angiotensin II receptor antagonist) or N-acetylcysteine.	Losartan	103-111	mitogen-activated protein kinase 8	Rattus norvegicus	19-22